News
2012
- 1/2012 Medovent started the commercialization of pure chitosan microfibers for tissue engineering research as well as reinforcement for medical implants.
Medoderm starts clinical study - first patients treated with chitosan woundspray.
····································································································································
2011
- Medovent gains certification according to EN ISO 13485:2003 to develop and manufacture sutures and other products for woundcare as well as medical implants based on chitosan.
····································································································································
2010
- 4/2010
Series B round of financing.
- 3/2010
Medoderm GmbH founded.
- 2/2010
Patent on Chitosan sutures filed.
····································································································································
2009
- 10/2009
Medovent installs modern clean rooms to fabricate medical devices according to GMP requirements.
- 6/2009
Approval of a collaborative project between Medovent and MfD Diagnostics (Wendelsheim/Germany) by the Federal Ministry of economic affairs and technology.
- 5/2009
An international patent application on a novel chitosan coating has been filed with the European patent office.
- 4/2009
Medovent closes its series A round of financing. The new funding is provided by a group of renowned private and institutional investors.
····································································································································
2008
- 12/2008
A project focussing on the development of chitosan coatings has been approved for funding by the Ministry of economic affairs, transport, agriculture and viticulture of Rhineland- Palatinate
- 6/2008
Medovent receives funding for an innovation assistant project, aiming at the development of novel chitosan based sutures.
- 5/2008
Medovent licenses chitosan technology to a global medical device company. The deal includes milestone and royalty payments, aiming at the market launch of an innovative chitosan-based product in urology.
····································································································································
2007
- 12/2007
Successful completion of biocompatibility and biodegradation testing of chitosan stents in a large animal model.
- 7/2007
A chitosan study in a small animal model has been completed, revealing a high biocompatibility and strong antibacterial properties of Medovent's materials.
- 4/2007
An international patent application on the controlled degradation of chitosan implants has been filed with the European patent office.
- 1/2007
Medovent is winner of the nation-wide contest "Best business idea" within the chamber of commerce region of Mainz.
····································································································································
2006
- 10/2006
An international patent application on the procesing of chitosan has been filed with the European patent office.
- 10/2006
Medovent closes its seed round of financing with High Tech Gründerfonds as lead investor.
- 9/2006
The company starts its business operations and moves in office and lab space at the biotech centre in Mainz.
- 8/2006
Medovent is founded by Dr. Thomas Freier and Dr. Rivelino Montenegro in Mainz/Germany.